| scholarly article | Q13442814 |
| P50 | author | Robert B Belshe | Q89722116 |
| Harvey M. Friedman | Q89912954 | ||
| P2093 | author name string | Sita Awasthi | |
| P2860 | cites work | Blocking antibody access to neutralizing domains on glycoproteins involved in entry as a novel mechanism of immune evasion by herpes simplex virus type 1 glycoproteins C and E | Q24646778 |
| Herpes simplex virus type 2 glycoprotein E is required for efficient virus spread from epithelial cells to neurons and for targeting viral proteins from the neuron cell body into axons | Q34071917 | ||
| Herpes simplex virus type 1 glycoprotein e is required for axonal localization of capsid, tegument, and membrane glycoproteins | Q34092761 | ||
| Herpes simplex virus type 1 and 2 glycoprotein C prevents complement-mediated neutralization induced by natural immunoglobulin M antibody. | Q34545821 | ||
| Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compa | Q35275146 | ||
| Efficacy results of a trial of a herpes simplex vaccine | Q35780697 | ||
| Glycoprotein D of herpes simplex virus (HSV) binds directly to HVEM, a member of the tumor necrosis factor receptor superfamily and a mediator of HSV entry | Q35890209 | ||
| Genital HSV-1 infections | Q36930524 | ||
| Blocking Immune Evasion as a Novel Approach for Prevention and Treatment of Herpes Simplex Virus Infection | Q37060288 | ||
| Immunization with HSV-1 glycoprotein C prevents immune evasion from complement and enhances the efficacy of an HSV-1 glycoprotein D subunit vaccine | Q37439603 | ||
| Correlate of immune protection against HSV-1 genital disease in vaccinated women | Q37604473 | ||
| Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA. | Q38050485 | ||
| Oligomeric structure of glycoproteins in herpes simplex virus type 1. | Q39876081 | ||
| Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes | Q57076537 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Herpes simplex virus type 1 | Q655331 |
| Human herpesvirus 2 | Q18965147 | ||
| P304 | page(s) | 571-575 | |
| P577 | publication date | 2014-03-20 | |
| P1433 | published in | Journal of Infectious Diseases | Q4051141 |
| P1476 | title | Better neutralization of herpes simplex virus type 1 (HSV-1) than HSV-2 by antibody from recipients of GlaxoSmithKline HSV-2 glycoprotein D2 subunit vaccine | |
| P478 | volume | 210 |
| Q34520389 | A Highly Efficacious Herpes Simplex Virus 1 Vaccine Blocks Viral Pathogenesis and Prevents Corneal Immunopathology via Humoral Immunity |
| Q57072187 | A new era in cytomegalovirus vaccinology: considerations for rational design of next-generation vaccines to prevent congenital cytomegalovirus infection |
| Q34501866 | A novel HSV-2 subunit vaccine induces GLA-dependent CD4 and CD8 T cell responses and protective immunity in mice and guinea pigs. |
| Q90700306 | A vaccine containing highly purified virus particles in adjuvant provides high level protection against genital infection and disease in guinea pigs challenged intravaginally with homologous and heterologous strains of herpes simplex virus type 2 |
| Q34549656 | An HSV-2 Trivalent Vaccine Is Immunogenic in Rhesus Macaques and Highly Efficacious in Guinea Pigs. |
| Q34580831 | Anti-glycoprotein g antibodies of herpes simplex virus 2 contribute to complete protection after vaccination in mice and induce antibody-dependent cellular cytotoxicity and complement-mediated cytolysis |
| Q34923432 | Antiviral activity of a single-domain antibody immunotoxin binding to glycoprotein D of herpes simplex virus 2. |
| Q41928445 | Biologic interactions between HSV-2 and HIV-1 and possible implications for HSV vaccine development |
| Q34057952 | Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes |
| Q62711973 | Cell-to-cell spread-blocking activity is extremely limited in the sera of HSV-1 and HSV-2 infected subjects |
| Q64078007 | Correlation between herpes simplex virus neutralizing antibody titers determined by ELVIS cell and traditional plaque reduction assays |
| Q40717625 | Development of a high-throughput β-Gal-based neutralization assay for quantitation of herpes simplex virus-neutralizing antibodies in human samples |
| Q33834821 | Global sensing of the antigenic structure of herpes simplex virus gD using high-throughput array-based SPR imaging |
| Q35156674 | Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease. |
| Q35866976 | Higher Throughput Quantification of Neutralizing Antibody to Herpes Simplex Viruses |
| Q38241377 | Improving immunogenicity and efficacy of vaccines for genital herpes containing herpes simplex virus glycoprotein D. |
| Q89574699 | Intramuscular vaccination of mice with the human herpes simplex virus type-1(HSV-1) VC2 vaccine, but not its parental strain HSV-1(F) confers full protection against lethal ocular HSV-1 (McKrae) pathogenesis |
| Q45323563 | Meeting report: Initial World Health Organization consultation on herpes simplex virus (HSV) vaccine preferred product characteristics, March 2017. |
| Q90627411 | Murine Model of Maternal Immunization Demonstrates Protective Role for Antibodies That Mediate Antibody-Dependent Cellular Cytotoxicity in Protecting Neonates From Herpes Simplex Virus Type 1 and Type 2 |
| Q35973512 | Patient-Specific Neutralizing Antibody Responses to Herpes Simplex Virus Are Attributed to Epitopes on gD, gB, or Both and Can Be Type Specific |
| Q33900262 | Repertoire of epitopes recognized by serum IgG from humans vaccinated with herpes simplex virus 2 glycoprotein D |
| Q45324844 | Reply to "Highly Efficacious Novel Vaccine, Humoral Immunity, and Ocular Herpes Simplex Virus 1: Reality or Myth?" |
| Q38650844 | The Neonatal Fc Receptor and Complement Fixation Facilitate Prophylactic Vaccine-Mediated Humoral Protection against Viral Infection in the Ocular Mucosa. |
| Q90290839 | The Roles of Host and Viral Antibody Fc Receptors in Herpes Simplex Virus (HSV) and Human Cytomegalovirus (HCMV) Infections and Immunity |
| Q38947826 | The emerging role of biosensor-based epitope binning and mapping in antibody-based drug discovery |
| Q34992660 | Topical herpes simplex virus 2 (HSV-2) vaccination with human papillomavirus vectors expressing gB/gD ectodomains induces genital-tissue-resident memory CD8+ T cells and reduces genital disease and viral shedding after HSV-2 challenge |
| Q38243160 | Update on baculovirus as an expression and/or delivery vehicle for vaccine antigens |
| Q36846035 | Vaccination with the Secreted Glycoprotein G of Herpes Simplex Virus 2 Induces Protective Immunity after Genital Infection |
| Q91168571 | Vaccine-induced antibodies target sequestered viral antigens to prevent ocular HSV-1 pathogenesis, preserve vision, and preempt productive neuronal infection |
| Q55406946 | Vaccine-induced antibodies to herpes simplex virus glycoprotein D epitopes involved in virus entry and cell-to-cell spread correlate with protection against genital disease in guinea pigs. |
| Q91766368 | Vaccines to prevent genital herpes |
Search more.